Interestingly, some recent therapies are not designed to directly kill cancer cells but rather to limit their plasticity induced by signals such as TGF-β; hence, combinatorial approaches, such as immune checkpoint blockade therapy or chemotherapy, are now being combined with TGF-β inhibitors [46]. This evidence concerns the gene TGFB1 and cancer.